Statin therapy in heart failure: Prognostic effects and potential mechanisms

The use of statins as therapy for heart failure remains controversial. Nevertheless, many of the pleiotropic effects of statins are potentially applicable in heart failure. Although early statin trials excluded patients with heart failure because of concerns that lowering serum cholesterol could wor...

Full description

Saved in:
Bibliographic Details
Published in:The American heart journal 2007-10, Vol.154 (4), p.617-623
Main Authors: Shanes, Jeffrey G., MD, Minadeo, Kira N., BS, Moret, Ann, APRN, BC, Groner, Mordechai, BA, Tabaie, Sean A., BS, MS
Format: Article
Language:English
Subjects:
Animals
Biological and medical sciences
Cardiology. Vascular system
Cardiovascular
Cholesterol
Cholesterol - blood
Coronary Disease - blood
Coronary Disease - complications
Disease Progression
Drug therapy
Heart
Heart - drug effects
Heart attacks
Heart Failure - drug therapy
Heart Failure - etiology
Heart Failure - physiopathology
Heart Failure - prevention & control
Heart failure, cardiogenic pulmonary edema, cardiac enlargement
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
Medical sciences
Mortality
Myocardial Infarction - mortality
Prognosis
Statins
Ventricular Function, Left - drug effects
Ventricular Remodeling - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The use of statins as therapy for heart failure remains controversial. Nevertheless, many of the pleiotropic effects of statins are potentially applicable in heart failure. Although early statin trials excluded patients with heart failure because of concerns that lowering serum cholesterol could worsen an already poor prognosis, statin treatment has not been shown to have adverse effects on either cardiovascular events or mortality, and recent experimental and clinical studies have shown promise of benefit. Two large, ongoing trials should provide definitive evidence of the value of statin therapy for patients with heart failure. Pending those results, it is reasonable to follow current National Cholesterol Education Program guidelines in this high-risk population.
ISSN:0002-8703
1097-6744
DOI:10.1016/j.ahj.2007.05.020